Open Access
CC BY-NC-ND 4.0 · J Lab Physicians 2022; 14(03): 317-323
DOI: 10.1055/s-0042-1748825
Original Article

Adaptation of a Public–Private Partnership Model for the Implementation of Minipool Nucleic Acid Testing for Screening Routine Blood Donations and Assay Evaluation

Smita Mahapatra
1   Department of Transfusion Medicine, Sri-Rama Chandra Bhanja Medical College & Hospital, Cuttack, Odisha, India
,
Pankaj Parida
1   Department of Transfusion Medicine, Sri-Rama Chandra Bhanja Medical College & Hospital, Cuttack, Odisha, India
,
Chitta Ranjan Prasad
2   Department of Transfusion Medicine, Veer Surendra Sai Institute of Medical Sciences and Research, Burla, Odisha, India
,
Sabita Palai
4   Transfusion Medicine, Maharaja Krishna Chandra Gajapati Medical College Hospital, Berhampur, Odisha, India
,
Debashis Mishra
3   Blood Bank, Capital Hospital, Bhubaneswar, Odisha, India
,
Susmita Behera
4   Transfusion Medicine, Maharaja Krishna Chandra Gajapati Medical College Hospital, Berhampur, Odisha, India
,
Rabindra Kumar Mishra
4   Transfusion Medicine, Maharaja Krishna Chandra Gajapati Medical College Hospital, Berhampur, Odisha, India
,
Binayak Prasad Prusty
5   Central Red Cross Blood Bank, Cuttack, Odisha, India
,
Kalyan Sarkar
6   BMC Hospital, Bhubaneswar, Odisha, India
› Institutsangaben

Funding None.
Preview

Abstract

Background Nucleic acid amplification testing (NAT) for the screening of blood donations is known to improve blood safety. The decision to initiate NAT requires careful deliberation of infrastructure, skilled manpower, and financial resources. This report outlines the initiative of the Government of Odisha to implement NAT screening in government blood banks in the state of Odisha, India, through public–private partnership (PPP) and evaluates the incremental yield of minipool NAT screening over serology testing of blood donations.

Methods Blood donations collected between June 2016 and September 2018 were initially screened for HBV (HBsAg), HCV (anti-HCV), and HIV (anti-HIV-1 and HIV-2) by ELISA, and syphilis and malaria. Sero-nonreactive donations were further screened in pools of six by Roche cobas TaqScreen MPX test version 2.0 (MPX2) NAT.

Results On screening 3,39,472 blood donations, 1.34% seroreactive donations were detected. In all, 847 NAT-reactive donations (0.26%): 693 HBV, 58 HCV, and 96 HIV were detected. The NAT yields were 1:386 overall, 1:472 for HBV, 1:5642 for HCV, and 1:3409 for HIV.

Conclusion NAT testing using the highly sensitive MPX2 assay leads to incremental detection of TTIs over serology. Implementation of NAT along with serological testing in blood centers all over India will be an important step towards providing safe blood. Our study not only highlights the benefits of minipool NAT testing but also presents a scalable PPP model that can serve as a template for application across other states.

Authors' Contributions

All the authors contributed to the concept, design, data collection, data analysis, interpretation of data, and critically reviewing the manuscript. All authors approved the final version of the manuscript.




Publikationsverlauf

Artikel online veröffentlicht:
10. Juni 2022

© 2022. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India